<DOC>
	<DOC>NCT01329640</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, effectiveness and cost-effectiveness of metronomic chemotherapy combined with trastuzumab as neoadjuvant therapy for locally advanced HER2-positive breast cancer.</brief_summary>
	<brief_title>Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Diagnosis of locally advanced breast cancer T &gt; 2 cm (any N), or any T and positive node(needle biopsy is required if tumor size is less than 2cm) Nonmetastatic disease confirmed by computerized tomography and bone scan HER2 positive by IHC (+++) and/or Fish (+) according to international definitions (ASCO 2007) Normal left ventricular ejection fraction (LVEF) Indication of preoperative chemotherapy multifocal tumors acceptable provided that the largest tumor is Her2positive ECOG 01 Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast) Clinically significant comorbidities such as cardiovascular diseases, COPD, renal or liver impairment, psychiatric disorders LVEF value below institutional limits of normal range Detected or suspected distant metastasis Neutrophils lower than 1,500/µL, platelets lower than 100,000/µL, hemoglobin lower than 10 g/dL, AST higher than 2.5x upper limit of normal (ULN), total bilirubin higher than ULN, alkaline phosphatase more than 1.5x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Metronimic chemotherapy</keyword>
	<keyword>Locally Advanced HER2-positive Breast Cancer</keyword>
</DOC>